for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Neurocrine Biosciences, Inc.

NBIX.O

Latest Trade

95.12USD

Change

-0.69(-0.72%)

Volume

858,255

Today's Range

93.45

 - 

96.94

52 Week Range

72.14

 - 

136.26

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
95.81
Open
95.58
Volume
858,255
3M AVG Volume
20.44
Today's High
96.94
Today's Low
93.45
52 Week High
136.26
52 Week Low
72.14
Shares Out (MIL)
93.43
Market Cap (MIL)
8,951.45
Forward P/E
71.80
Dividend (Yield %)
--

Next Event

Neurocrine Biosciences Inc at Evercore ISI HealthCONx Conference

Latest Developments

More

Neurocrine Biosciences Reports Q3 Loss Per Share $0.62

Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy Of FDA-Approved Once-Daily Ongentys In Patients With Parkinson's Disease

Neurocrine Biosciences Q2 Earnings Per Share $0.81

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Industry

Biotechnology & Drugs

Contact Info

12780 El Camino Real

SAN DIEGO, CA

92130-2042

United States

+1.858.6177600

http://www.neurocrine.com/

Executive Leadership

William H. Rastetter

Independent Chairman of the Board

Kevin C. Gorman

Chief Executive Officer, Director

Matthew C. Abernethy

Chief Financial Officer

Julie Cooke

Chief Human Resource Officer

Eric S. Benevich

Chief Commercial Officer

Key Stats

2.00 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.5K

2019

0.8K

2020(E)

1.1K
EPS (USD)

2017

-1.620

2018

0.220

2019

0.390

2020(E)

1.334
Price To Earnings (TTM)
103.19
Price To Sales (TTM)
8.59
Price To Book (MRQ)
11.13
Price To Cash Flow (TTM)
87.85
Total Debt To Equity (MRQ)
52.84
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
9.55
Return on Equity (TTM)
6.96

Latest News

Latest News

Neurocrine launches Parkinson's therapy as COVID-19 related disruptions ease

Neurocrine Biosciences Inc on Monday launched its add-on treatment for patients with Parkinson's disease nearly five months after Food and Drug Administration's approval, as the COVID-19 pandemic delayed its roll out in the United States.

BRIEF-Neurocrine Biosciences, Takeda Announce Collaboration To Develop Potential Therapies For Psychiatric Disorders

* NEUROCRINE BIOSCIENCES AND TAKEDA ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE POTENTIAL THERAPIES FOR PSYCHIATRIC DISORDERS

BRIEF-Neurocrine Biosciences Reports Positive Phase Ii Data For Crinecerfont In Adults With Congenital Adrenal Hyperplasia At Endo Online 2020

* NEUROCRINE BIOSCIENCES INC - REPORTS POSITIVE PHASE II DATA FOR CRINECERFONT IN ADULTS WITH CONGENITAL ADRENAL HYPERPLASIA AT ENDO ONLINE 2020

BRIEF-Idorsia: Neurocrine Biosciences Exercises Option To License Idorsia's Novel Treatment For Rare Pediatric Epilepsy

* NEUROCRINE BIOSCIENCES EXERCISES OPTION TO LICENSE IDORSIA'S NOVEL TREATMENT FOR RARE PEDIATRIC EPILEPSY

BRIEF-Neurocrine Biosciences Exercises Option To License Idorsia's Treatment For Pediatric Epilepsy

* NEUROCRINE BIOSCIENCES INC - EXERCISES OPTION TO LICENSE IDORSIA'S NOVEL TREATMENT FOR RARE PEDIATRIC EPILEPSY

Neurocrine gets U.S. nod for Parkinson's therapy; COVID-19 delays launch

Neurocrine Biosciences Inc said on Monday its add-on treatment for patients with Parkinson's disease received U.S. approval, but the launch will be delayed until later this year because of disruptions caused by the COVID-19 pandemic.

BRIEF-Neurocrine Biosciences Announces FDA Approval Of Once-Daily ONGENTYS

* NEUROCRINE BIOSCIENCES ANNOUNCES FDA APPROVAL OF ONCE-DAILY ONGENTYS® (OPICAPONE) AS AN ADD-ON TREATMENT FOR PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES

U.S. FDA approves Neurocrine's Parkinson's therapy

The U.S. Food and Drug Administration approved Neurocrine Biosciences Inc's add-on treatment for patients with Parkinson's disease, the company said on Monday.

BRIEF-Neurocrine Biosciences Provides Covid-19 Business Update

* NEUROCRINE BIOSCIENCES INC - COMPANY CONTINUES TO ASSESS ANY POTENTIAL IMPACT TO ITS BUSINESS GIVEN ONGOING NATURE OF PANDEMIC

Idorsia pairs with Neurocrine in potential $400 million epilepsy drug deal

Swiss biotech group Idorsia on Friday lifted the lid off a 2019 deal for its investigational epilepsy medicine, revealing the pact that is potentially worth more than $400 million is with U.S.-based Neurocrine Biosciences.

BRIEF-Idorsia And Neurocrine Biosciences Amend Option Agreement On Treatment For Pediatric Epilepsy

* NEUROCRINE BIOSCIENCES AND IDORSIA AMEND OPTION AGREEMENT TO LICENSE NOVEL TREATMENT FOR RARE PEDIATRIC EPILEPSY

BRIEF-Neurocrine Biosciences And Idorsia Amend Option Agreement To License Novel Treatment For Rare Pediatric Epilepsy

* NEUROCRINE BIOSCIENCES AND IDORSIA AMEND OPTION AGREEMENT TO LICENSE NOVEL TREATMENT FOR RARE PEDIATRIC EPILEPSY

BRIEF-Neurocrine Biosciences Q1 Loss Per Share $0.47

* NEUROCRINE BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

CORRECTED-FDA extends review for AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain

Abbvie And Neurocrine Biosciences Announce Pdufa Target Date Of Q3 2018 For Elagolix In Endometriosis :

BRIEF-Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data

* NEUROCRINE BIOSCIENCES WILL FILE NEW DRUG APPLICATION FOR OPICAPONE FOR PARKINSON'S DISEASE BASED ON EXISTING PIVOTAL CLINICAL TRIAL DATA

BRIEF-Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07

* NEUROCRINE BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES INVESTOR UPDATE FOR 2018

BRIEF-Neurocrine Biosciences Presents Long-Term Data Analyses From Open-Label Kinect 4 Phase III Study

* NEUROCRINE BIOSCIENCES PRESENTS LONG-TERM DATA ANALYSES FROM OPEN-LABEL KINECT 4 PHASE III STUDY DEMONSTRATING INGREZZA® IMPROVES TARDIVE DYSKINESIA SYMPTOMS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up